Context and Overall Objectives
The SeaBeEYE project, led by SeaBeLife, aimed to tackle significant unmet medical needs in the realm of retinal diseases, which can lead to severe vision loss and currently lack effective treatments. SeaBeLife, a French biotechnology company, has been at the forefront of developing first-in-class drug candidates to protect and regenerate organs impacted by serious pathologies. With the support of the Women TechEU grant, SeaBeLife embarked on an innovative journey to create advanced treatments for retinal diseases, focusing specifically on achieving proof-of-concept (POC) for novel vision protection technologies.
Activities and Achievements
The primary objective of the SeaBeEYE project was to develop and validate formulations designed for intravitreal (IVT) and ophthalmic gel applications. The project commenced with the development of two clinically relevant formulations:
(1)-Sustained Release Formulation for Intravitreal Administration: This formulation aimed to release the therapeutic agent over an extended period, enhancing treatment efficacy and patient compliance.
(2)-Ophthalmic Gel for Instillation: This innovative approach intended to provide a non-invasive route of administration, making treatment more accessible and patient-friendly.
Key partnerships played a crucial role in the project's success. A specialized Contract Research Organization (CRO) in France, was engaged to develop and produce prototypes for both formulations. They also conducted comprehensive in vitro characterizations and preliminary stability studies. Another key partner conducted in vivo pharmacokinetic evaluations using a rabbit model, demonstrating effective retinal delivery of the ophthalmic gel formulation.
Expected Impact:
The SeaBeEYE project is poised to make a significant impact in the field of ophthalmology by introducing new treatment paradigms for retinal diseases. The sustained release IVT formulation and the ophthalmic gel for instillation offer distinct advantages over current solutions, including prolonged drug release and non-invasive administration. These advancements are expected to improve patient outcomes, reduce the frequency of treatments, and enhance the overall quality of life for individuals suffering from retinal conditions.
Role of Social Sciences and Humanities:
While the primary focus of the SeaBeEYE project is scientific and technological, the integration of social sciences and humanities is implicit in its approach to patient care. By prioritizing non-invasive treatment methods and aiming to enhance patient compliance and accessibility, the project underscores the importance of patient-centric solutions in medical innovation.
Conclusion
The Women TechEU grant has been instrumental in propelling the SeaBeEYE project forward, enabling SeaBeLife to make significant strides in developing breakthrough treatments for retinal diseases. With continued efforts and further validation, these innovative formulations have the potential to transform the landscape of vision care and offer new hope to patients worldwide.
